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Lip cancerObjectives: Previous large studies have shown that solid organ transplant (SOT) patients have an
increased risk of developing malignancies. Few studies have compared the prognosis for SOT patients
who develop cancer with that of non-transplanted cancer patients. In this study we have investigated
the increased risk of oral and lip cancer in SOT patients and also compared the relative survival between
SOT patients and non-SOT patients with oral and lip cancer.
Patients and methods: From the patient registers at the Transplant Institute at Sahlgrenska University
Hospital, records of 4604 SOT patients from 1965 to 2010 were collected. These patient records were
linked to the nationwide Swedish Cancer Register and compared to those of the normal population
regarding the risk of developing oral and lip cancer, and also to non-SOT patients with lip and oral cancer.
A Poisson regression model was used to compare the relative survival between SOT and non-SOT patients
with oral and lip cancer.
Results: We observed 17 oral cancers (expected 2.69) and 34 lip cancers (expected 0.78) in the cohort.
The standardized incidence ratio (SIR) for oral cancer was 6.32 (95% CI, 3.7–10.1) and 43.7 (95% CI,
30.3–61.1) for lip cancer. Relative ﬁve-year survival for lip cancer was lower for SOT patients compared
to non-SOT patients (p < 0.001).
Conclusion: This study shows that SOT patients have a higher risk of developing both oral and lip cancer,
and in addition, that SOT patients with lip cancer have a worse prognosis.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Previous large epidemiological studies have shown an increased
risk of developing a wide range of malignant tumours following
solid organ transplantation (SOT) [1–5]. Improvement in the clini-
cal management of SOT patients leads to an increase in long-term
survival, and that results in an increased risk of developing cancer
over time [5].
The overall risk for malignant diseases is increased by at least
twice after transplantation, but the risk varies with type of organ
and type of malignancy [2,5,6]. Most of the known infection-relatedcancers – but also some non-infection related cancers – increase in
prevalence after transplantation [7]. Tumour diseases that show the
highest increase in prevalence in SOT patients are non-melanoma
skin cancers and post-transplant lymphoproliferative diseases
(PTLD) [2,8]. The increased risk of malignant diseases in SOT
patients is assumed to be a consequence of long-standing immuno-
suppression that leads to impaired immunosurveillance against
tumours. In addition, sun exposure is an important risk factor for
non-melanoma skin cancers. The overall cancer risk in SOT patients
has been shown to be higher amongst patients who received
thoracic organs compared to patients receiving abdominal organ
[4,6]. Also in the head-neck region there is an increase in cancer
incidence [9]. Head and neck cancers have been reported to consti-
tute 4–15% of all malignant tumours after transplantation [10–13].
An increased incidence of lip cancer has also been reported [14,15].
Treatment outcome of head and neck cancers in SOT patients seems
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state of immunosuppression [9,12].
Long-term survival increases for SOT patients, which is mostly
attributed to improvements in the early post-transplant phase;
however, malignancies in the late post-transplantation phase are
an increasing problem and pose a threat to survival for SOT
patients [5,16]. This warrants a close follow-up of cancer epidemi-
ology in SOT patients. Thus, the primary aim of this study was to
investigate the risk of oral and lip cancer in a Swedish patient
cohort treated with SOT between 1965 and 2012. The secondary
aim was to compare the prognosis for SOT patients with oral and
lip cancer in this cohort with a non-SOT cohort of patients with
oral and lip cancer.Patients and methods
Study population
The study cohort was selected after a retrospective search in the
register at the Transplant Institute at Sahlgrenska University Hos-
pital. We identiﬁed 5755 patients from the register, which contain
all SOT patients who were treated with transplantation between
January 1965 and December 2010. After exclusion of patients with
more than one transplantation (n = 1151), 4604 patients remained
and were the foundation for the analyses. By linking data for the
SOT cohort to the Swedish Cancer Registry, all patients in the
cohort diagnosed with cancer both before and after SOT were
identiﬁed. Patient data from the study cohort were then linked to
the cause of death register and the population register to explore
(1) cause of death if applicable, and (2) numbers of patients with
Swedish residency and those without.
Also, patients with a history of oral and lip cancer before SOT
and patients diagnosed within 30 days after SOT (n = 2) were
excluded. Twelve patients with missing data were excluded from
analysis. A cohort of 4590 SOT patients was then identiﬁed and
subsequently analysed.
The International Classiﬁcation of Diseases was used to identify
anatomical sites of tumours. Diagnoses were identiﬁed by ICD-7:
oral cancer 141–144 (major salivary gland 142), and lip cancer 140.
A control group, matched for sex and age, was selected from the
Cancer Registry, Region Västra Götaland, Sweden, and was used to
compare the relative survival for SOT patients with that of non-SOT
patients with oral and lip cancer. Oral cancer was diagnosed in
1849 non-SOT patients between 1975 and 2010, while 881 non-
SOT patients were diagnosed with lip cancer during the same time
frame.
In the survival analysis, one patient was excluded from the lip
SOT patient group because the patient had had an oral cancer
before the lip cancer, and two patients were excluded from the oral
cancer SOT patient group because of a preceding lip cancer.
The Ethical Review Board at the Sahlgrenska Academy,
University of Gothenburg, Sweden, approved this study.Statistical analyses
Relative risk of cancer in SOT patients compared to the general
population was expressed as standardized incidence ratio (SIR). A
95% conﬁdence interval (CI) and a p-value < 0.05 was considered
statistically signiﬁcant. Incidence rates in the Swedish population,
by gender, 5-year age group, and calendar year, were used to
calculate the expected number of cancer cases among the SOT
patients. A Poisson regression model was used to compare the
relative survival between SOT patients and non-SOT patients with
oral and lip cancer.Results
Analyses of study population
A total of 4590 SOT patients proceeded to analyses. The mean
and median ages at SOT were 47 years and 49 years, respectively
(range: 0–77 years). Follow-up was extended to date of death or
until 31 December 2010, resulting in a total of 37,270 person-years
of follow-up time.
In the cohort, 2839 were men (62%) and 1751 women (38%).
The study population comprised 437 heart, 359 lung, 710 liver,
and 3084 kidney recipients. Patient characteristics are given in
Table 1.Oral and lip cancer in our SOT cohort
In the study cohort of 4590 single-transplanted patients we
observed 17 oral cancers (0.4%) and 34 lip cancers (0.7%).
In the patient group with oral cancer the mean and median ages
at diagnosis were the same, 63 years (range: 49–72 years; Table 1).
In the patient group with lip cancer the mean and median ages at
diagnosis were 61 and 62 years, respectively (range: 34–80 years).
The majority of the patients in the lip cancer group (56%) were
diagnosed between 60 and 119 months after SOT, with a mean/
median time from SOT to diagnosis of 88/79 months (range:
27–212). During the corresponding time, 47% of the SOT patients
with oral cancer were diagnosed, and the mean/median time from
SOT to diagnosis was 128/113 months (range: 27–289).Standardized incidence ratio of oral and lip cancer
Among SOT patients, most oral and lip cancers were found in
kidney patients (oral n = 14, lip n = 24), followed by heart (oral
n = 2, lip n = 6), liver (oral n = 1, lip n = 3) and lung patients (oral
n = 0, lip n = 1) (Table 2).
The expected number of oral cancers in the cohort was 0.7, but
17 patients with oral cancer were found (SIR: 6.3, CI 3.7–10.1;
Table 2). The corresponding number for lip cancer was 0.8 but
we observed 34 patients with that diagnosis (SIR: 43.7, CI 30.3–
61.1; Table 2). Statistical comparisons show signiﬁcantly increased
risks for oral (p < 0.02) and lip cancer (p < 0.001) in SOT patients
compared with what was expected to occur in the Swedish popu-
lation. Subsite distribution of oral and lip cancers is presented in
Table 3.
The highest incidence of oral cancer was found in heart trans-
plant patients, with SIR of 8.7 (CI 1.05–31.4), followed by kidney,
SIR 6.9 (CI 3.8–11.6); liver, SIR 3.1 (CI 0.08–17.4); and lung trans-
plant patients, SIR 0 (Table 2). Lip cancer incidence was also high-
est among heart transplant patients, with a SIR value of 99.0 (CI
36.2–99.99) (Table 2). Lung, liver, and kidney transplant patients
showed SIR values at approximately the same level: lung trans-
plant recipients had a SIR value of 46.0 (CI 0.6–99.99); liver
patients, 41.6 (CI 8.35–9.99); and kidney patients, SIR 38.5 (CI
24.7–57.3) (Table 2).Survival analysis
Five-year relative survival for oral cancer patients with SOT
was 30.8% (CI 7.7–60.2%; Fig. 1A), and for patients with oral can-
cer without SOT it was 60.1% (CI 57.6–62.6%; Fig. 1A). Outcome
comparison between the groups did not show a signiﬁcant dif-
ference in relative survival (Fig. 1A; p = 0.14). Five-year relative
survival for single SOT patients with lip cancer was 66.0%
(CI 44.7–82.2%; Fig. 1B) and for lip cancer without SOT 94.2%
(CI 91.1–96.9%; Fig. 1B), which results in a signiﬁcantly reduced
Table 1
Patient characteristics.
All organs Heart Lung Liver Kidney
No. of patients (%) 4590 437 (9.5) 359 (7.8) 710 (15.5) 3084 (67.2)
Females 1751 (38) 105 (24) 209 (58) 269 (38) 1168 (38)
Males 2839 (62) 332 (75) 150 (42) 441 (62) 1916 (62)
Age at ﬁrst transplantation (%)
<20 5.1 14.7 4.5 7.3 3.3
20–34 15.0 11.0 12.3 10.1 16.9
35–44 18.7 14.7 13.9 14.8 20.7
45–54 26.7 28.6 31.8 25.9 26.0
55–64 27.9 28.8 32.0 33.4 26.1
P65 6.7 2.3 5.6 8.5 7.0
Mean/median age (range, years) 46.5/49.0 (0–77) 42.9/48.0 (0–70) 48.2/52.0 (7–73) 47.8/52.0 (0–73) 46.5/49.0 (0–77)
Year of ﬁrst transplantation
1965–69 88 0 0 0 88
1970–79 341 0 0 0 341
1980–89 726 52 0 0 674
1990–99 1362 192 130 200 840
2000–10 2073 193 229 510 1141
Follow-up time, median (range, years) 6.3 (0–43.4) 5.7 (0–23.0) 3.2 (0–20.9) 4.5 (0–17.9) 7.2 (0–43.4)
Follow-up time, total (person-years) 37,270 3192 1751 4031 28,297
Table 2
Standardized incidence ratios of oral and lip cancers in SOT patients.
Oral cancer Lip cancer
Transplanted organ Obsa Exp.b SIRc CId p-valuee Obs.a Exp.b SIRc CId p-valuee
All organs 17 2.69 6.3 (3.7–10.1) <0.001 34 0.78 43.7 (30.3–61.1) <0.001
Heart 2 0.23 8.7 (1.05–31.4) <0.05 6 0.06 99.0 (36.2–99.99) <0.001
Lung 0 0.11 0 – – 1 0.02 46.0 (0.6–99.99) <0.05
Liver 1 0.32 3.1 (0.08–17.4) n.s. 3 0.07 41.6 (8.35–9.99) <0.001
Kidney 14 2.03 6.9 (3.8–11.6) <0.001 24 0.62 38.5 (24.7–57.3) <0.001
a No. of observed cancers.
b No. of expected cancers.
c Standardized incidence ratio.
d 95% conﬁdence interval.
e p-value < 0.05 is considered signiﬁcant.
Table 3
Subsite distribution of oral and lip cancers in SOT patients
according to ICD-7 classiﬁcation.
Localization (ICD-7) Number of cancers
Upper lip (140.0) 3
Lower lip (140.1) 17
Lip unspeciﬁed (140.9) 14
Tongue (141) 4
Major salivary glands (142) 5
Floor of mouth (143) 3
Gingiva, palate, bucca (144) 5
148 J. Öhman et al. / Oral Oncology 51 (2015) 146–150relative survival for SOT patients with lip cancer (Fig. 1B;
p < 0.001).
The observed survival rates for SOT patients were 27% and 61%
alive at ﬁve years after oral and lip cancer, respectively (Fig. 2).Discussion
Our study shows that the risk for oral cancer increased 6 times,
and for lip cancer 44 times in our cohort of SOT patients. Fewer
than 1% of the patients developed oral or lip cancer. The relative
survival for patients who developed lip cancer following SOT was
signiﬁcantly decreased in comparison with non-SOT patients, but
no signiﬁcant difference in relative survival could be registered
when comparing SOT patients who developed oral cancer with
non-SOT patients. In the present study we chose to exclude
patients with more than one organ transplantation. Patients withmore than one SOT constitute a heterogeneous group with respect
having a more complicated medical situation and a complex phar-
macological treatment including immunosuppression, as well as
longer duration of this treatment, compared with those having
one SOT. Analysis of a single-SOT cohort thus provides a baseline
level of cancer risk amongst the SOT patients.
The increased risk of tumour development amongst SOT
patients has been conﬁrmed by several large epidemiological
studies [1,2,4,5]. In SOT patients long-standing pharmacological
immunosuppression results in impaired function of the immune
system, which is a prerequisite for good, long-term transplant
function. As a consequence, the risk of spontaneously emerging
cancer cells avoiding elimination by the immune system not only
increases but also opens a pathway where oncoviruses like human
papilloma virus and Epstein–Barr virus may induce tumours more
often than otherwise. Exogenous factors like UV radiation from the
sun in combination with impaired immunosurveillance have been
related to the increased prevalence of skin cancers observed in SOT
patients [17,18]. The loss of immunosurveillance most certainly
plays an important role in development of post-transplant
malignancies. Clinical evidence has been presented which suggests
that the immune system plays an important role regarding the
progression and the prognosis of malignant tumours in non-SOT
patients [19–21].
This study focuses on investigating two nearby but different
anatomical regions: the oral cavity and the lips. Immunosuppres-
sion, viruses, and environmental factors inﬂuence the oral cavity
and lips in a similar manner, but the oral cavity is shielded from
UV radiation, in contrast to the lips. In our patient cohort oral
Fig. 1. Relative survival for (A) SOT patients with oral cancer (solid line) and control patients with oral cancer (dotted line), and (B) for SOT patients with lip cancer (solid line)
and control patients with lip cancer (dotted line).
Fig. 2. Observed survival for SOT patients with oral cancer (dotted line) and lip
cancer (solid line).
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Canadian SOT patient cohort there was an almost ninefold increase
in oral and pharyngeal cancer [1], while a UK transplant centre
reported a fourfold increase in oral cancer [3]. In a US patient
cohort oral and pharyngeal cancers presented with a 2.5 times
increase in risk [2]. Thus, results presented in this study are in line
with and conﬁrm that the increase in risk of oral cancer following
SOT most likely lies in the range between three to eight times.
In contrast, lip cancer developed 44 times more frequently than
expected amongst our patients. Earlier studies have also reported a
more than 10-fold increase in lip cancer following SOT, which
parallels the general risk increase in risk for non-melanoma skin
cancers in these patients [1,2,22]. In a US cohort a 17 times
increase in lip cancer was registered, but in contrast, in a UK cohort
lip cancer occurred 66 times more frequently than expected [2,3].
The range in lip cancer frequencies between the cohorts may
possibly be explained by differences in exposition to sunlight and
skin constitution.
Several centres have conﬁrmed an organ-speciﬁc, signiﬁcant
difference in overall cancer incidence in SOT patients. Transplanta-
tion of heart or/and lung has the highest risk of cancer develop-
ment [4,6]. This fact has been attributed to the higher level of
immunosuppressive treatment in this group in comparison with
regimens applied in transplantation of other organs. Despite the
relatively low numbers of oral and lip cancers the standard inci-
dence rates in heart or lung SOT patients in our cohort surpassedwhat was registered in liver and kidney SOT patients. Thus, this
study presents further evidence that heart and lung SOT patients
are at high risk of tumour development in comparison with other
organ transplantation patients. It can be speculated whether this
is a result of the level of immunosuppression; however, this we
cannot answer, since the level of immunosuppression was not
monitored in our database. New regimens of immunosuppressive
treatment following SOT may inﬂuence tumour development,
which in the future certainly will inﬂuence cancer risk in SOT
patients [24]. In our study we cannot address the impact of new
regimens because of the relatively low number of patients con-
tracting oral or lip cancer.
In the general population it is well investigated that exposure to
tobacco and alcohol increase the risk for oral cancer [25], and UV
exposure has been shown to be the main risk factor for both mel-
anoma and non-melanoma skin cancers, including cancers of the
facial skin [26]. Globally, oral cancer has the highest incidence in
parts of Asia, in Eastern Europe, and in parts of Latin America
[23]. However, to our knowledge no large cohort studies from
centres in those regions have been presented, which makes com-
parison of a global variation in cancer incidence in SOT patients
difﬁcult.
Few studies have speciﬁcally evaluated survival outcome of SOT
patients who develop oral or lip cancer. In a recent study, Nelissen
and co-workers reported the overall ﬁve-year survival for head and
neck tumours in a Belgian SOT patient cohort to be slightly more
than 50% [9]. In an Israeli cohort the ﬁve-year overall survival rate
was 74% for head and neck malignancies [13]. In a nationwide
study of all SOT patients transplanted in Sweden between 1970
and 1997 Adami and collaborators [27] report standard incidence
ratios for oral and lip cancer in accordance with our ﬁndings. How-
ever, our single centre study has longer follow up time and also
addresses survival outcome for SOT patients that contracted oral
or lip cancer in our cohort. We evaluated survival outcome for
SOT patients who contracted oral or lip cancer in our cohort. The
relative survival for patients who contracted lip cancer was signif-
icantly decreased in comparison with lip cancer patients without
SOT. In SOT patients with oral cancer no statistically signiﬁcant dif-
ference was observed when these were compared with non-SOT
patients with oral cancer, although data in our statistical analysis
may indicate a trend.
Many factors may be involved in the worse outcome of SOT
patients with lip and possibly oral cancer in our cohort compared
to a matched group of non-SOT patients with these diagnoses. A
principal cause, as pointed out by several groups, is the longstand-
ing immunosuppression that SOT patients are subjected to and the
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treatment of head-neck cancers may have to be modiﬁed because
of the patient’s medical condition in general, which inﬂuences
treatment efﬁcacy. The worldwide trends in incidence of oral and
oropharyngeal cancer show a changing pattern with an increase
in oropharyngeal cancers during the last two decades, while oral
cancer incidence displays a more heterogeneous pattern [28]. This
calls for close monitoring of changes in incidence of head and neck
cancers also in SOT patients.
Conclusion
The present study veriﬁes an increased risk of oral and lip can-
cer in SOT patients. We also report a decrease in relative survival
for lip cancer and possibly also for oral cancer.
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